EBONY MILLER: Open Payments
NPI 1093371759 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,015 in 91 payments from 17 companies in 2025. Trend: 2023 $14 · 2024 $2,281 · 2025 $2,015
Food & beverage: $2,015
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $479 |
| ABBVIE INC. | 16 | $273 |
| Amgen Inc. | 11 | $269 |
| Incyte Corporation | 13 | $198 |
| Galderma Laboratories, L.P. | 10 | $141 |
| UCB, Inc. | 6 | $135 |
| Janssen Biotech, Inc. | 4 | $106 |
| Arcutis Biotherapeutics, Inc. | 4 | $93 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 4 | $86 |
| Novartis Pharmaceuticals Corporation | 4 | $86 |
Products named: DUPIXENT, OTEZLA, OPZELURA, SKYRIZI, NEMLUVIO, Bimzelx, RINVOQ, TREMFYA.
Industry payments across CA — which companies pay providers there.
